PCM
DYN icon

Pavaki Capital Management’s Dyne Therapeutics DYN Stock Holding History

Pavaki Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$444K Hold
20,000
– – 0.15% 97
2026
Q1 		$363K Buy
+20,000
New +$345K 0.15% 98

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Pavaki Capital Management's DYN Position: Q2 2026 in Review

Pavaki Capital Management held its Dyne Therapeutics (DYN) position steady in Q2 2026 at 20,000 shares worth $444K. The position accounts for 0.15% of the portfolio, ranked #97.

Pavaki Capital Management first reported a position in DYN in Q1 2026 and has held it in 2 quarters since. 230 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Pavaki Capital Management held 20,000 shares of Dyne Therapeutics worth $444K as of Q2 2026.
  • Pavaki Capital Management left its Dyne Therapeutics share count unchanged in Q2 2026.
  • Dyne Therapeutics made up 0.15% of Pavaki Capital Management's portfolio in Q2 2026, its #97 holding.
  • Pavaki Capital Management first reported a position in Dyne Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 230 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Pavaki Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.